title: Treatment of skull base tumors.
abstract: The rich multidisciplinary environment in which skull base surgery has developed has allowed for significant progress in the field and has improved patient outcomes. More precise and detailed anatomic dissection in the laboratories has provided surgeons with the benefit of undertaking the serious technical challenges encountered in the skull base. Significant work has been done and continues to be developed in the field of adjuvant treatments including radiotherapy, chemotherapy, and hormonal therapy. Using biologic end points and specific genetic targets in the tumors may further expand our management options in the future.
authors.affiliation: Department of Neurosurgery, M.D. Anderson Cancer Center, Box 442, 1515 Holcombe Boulevard, Houston, TX 77021, USA. sprabhu@mdanderson.org
authors.forename: Sujit S
authors.initials: SS
authors.lastname: Prabhu
authors.forename: Franco
authors.initials: F
authors.lastname: Demonte
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008579:Meningioma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D009442:Neurilemmoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009493:Neurosurgery / Q000379:methods; D011379:Prognosis; D016634:Radiosurgery / Q000379:methods; D011882:Radiotherapy, High-Energy / Q000379:methods; D018570:Risk Assessment; D019291:Skull Base; D015996:Survival Rate; D016896:Treatment Outcome